Novatek International selected as partner for automation of Boehringer Ingelheim's global environmental monitoring program
NOVA-EM is Novatek's solution dedicated to managing all aspects of an automated environmental monitoring program.
Novatek International has been selected by Boehringer Ingelheim as their approved vendor and partner for a worldwide solution for environmental monitoring software. Boehringer Ingelheim plans to implement and validate the NOVA-EM (Environmental Monitoring) solution at multiple sites worldwide.
After considering the time and cost of customizing and configuring their current LIMS and ERP systems to make a customized solution for environmental monitoring (EM), Boehringer Ingelheim decided to go with a dedicated solution for their EM needs.
NOVA-EM from Novatek International was chosen as the global standard by Boehringer Ingelheim following a thorough RFP process, involving several vendors, and evaluation of the available LIMS and EM solutions.
NOVA-EM is Novatek's solution dedicated to managing all aspects of an automated Environmental Monitoring Program. NOVA-EM is a business-ready, process-specific 'off-the-shelf' solution that meets 95+ percent of environmental monitoring automaton requirements out of the box. As a GAMP 5 category 3 software system, implementing NOVA-EM equates rapid installation, implementation, validation, and deployment. The time and cost savings, in contrast to configurable systems, is undeniable and a key reason for the selection of the NOVA-EM solution.
Novatek's modular approach combined with a globally proven deployment process, provides Boehringer Ingelheim a clear and concise roadmap to plan and add additional off the shelf, process-specific modules such as Cleaning Validation Management (NOVA-CVM) to create a larger solution for complete contamination control.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.